ライフサイエンスコーパス: cytosine arabinoside

1 60 mg/m(2) on days 1, 3, and 5 combined with cytosine arabinoside.

2 t occur after treatment with doxorubicin and cytosine arabinoside.

3 n organotypic cerebellar cultures exposed to cytosine arabinoside.

4 any of these drugs) or greater than 7.5 g of cytosine arabinoside.

5 25 mg/m2/d IV CI over 24 hours, days 1 to 4; cytosine arabinoside 1.5 g/m2/d IV over 2 hours on day 5

6 ed in significantly increased sensitivity to cytosine arabinoside, accompanied by significantly decre

7 tively sensitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MIP-1alpha c

8 Phase III randomized trial of standard dose cytosine arabinoside and daunomycin + rhG-CSF).

9 ion synergistically enhanced cytotoxicity of cytosine arabinoside and doxorubicin in AML blasts but n

10 l to a chemotherapeutic induction regimen of cytosine arabinoside and idarubicin hydrochloride, with

11 olus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active i

12 By treating the neurons with combined cytosine arabinoside and NGF withdrawal, we demonstrate

13 chemotherapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a va

14 the presence of the DNA synthesis inhibitor cytosine arabinoside and transfected with plasmids conta

15 ve to the chemotherapeutic agents etoposide, cytosine arabinoside, and Adriamycin.

16 , as evidenced by blocking neurogenesis with cytosine arabinoside, and helps to preserve the hippocam

17 drol = methylprednisolone, High-dose Ara-C = cytosine arabinoside, and Platinum = cisplatinum), in a

18 ycles of CHOEP and 1 cycle of dexamethasone, cytosine-arabinoside, and platinum (DHAP) followed by hi

19 ed by AG1295 was compared to the response to cytosine arabinoside (Ara C) and correlated with the pre

20 ed in vitro sensitivity of DS myeloblasts to cytosine arabinoside (ara-C) and daunorubicin and the gr

21 Cytosine arabinoside (ara-C) and gemcitabine (dFdC) are

22 y 5'-phosphonate derivatives of cytidine and cytosine arabinoside (ara-C) have been prepared via phos

23 Cytosine arabinoside (ara-C) is a cytidine analog that i

24 to those with non-DS AML, linked to greater cytosine arabinoside (ara-C) sensitivity and higher tran

25 an display de novo or acquired resistance to cytosine arabinoside (Ara-C), a primary component of ind

26 of intracerebroventricular (ICV) infusion of cytosine arabinoside (Ara-C), an inhibitor for cell prol

27 -amino-5'-phosphono derivatives of cytidine, cytosine arabinoside (ara-C), and uridine have been prep

28 n of INPP4B conferred leukemic resistance to cytosine arabinoside (ara-C), daunorubicin, and etoposid

29 r in vitro treatments with daunomycin (DNR), cytosine arabinoside (ARA-C), or gamma irradiation (RAD)

30 comparison to the standard chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific

31 omal cells, exhibited up to 1.7-fold reduced cytosine arabinoside (ara-C)-induced apoptosis, compared

32 ), hydroxyurea (HU), daunorubicin (DNR), and cytosine arabinoside (Ara-C).

33 ednisone, 2-Chlorodeoxyadenosine (2-CdA), or cytosine arabinoside (ARA-C).

34 ight in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has b

35 Exposure to low-dose cytosine arabinoside (Ara-C; 10 nmol/L) increased hemogl

36 nduction chemotherapy regimens consisting of cytosine arabinoside (Ara-C; A), daunorubicin (D), and e

37 GG1 have enhanced sensitivity to cytarabine (cytosine arabinoside [Ara-C]) relative to OGG1-proficien

38 y of anticancer and antiviral agents such as cytosine arabinoside (araC) and gemcitabine.

39 our investigation of DNA-damaging agents to cytosine arabinoside (AraC) and UV irradiation.

40 Cytosine arabinoside (araC) is an important drug used fo

41 The cells were then treated with either beta-cytosine arabinoside (araC) or caffeine, and chromatid b

42 We evaluated the delivery of 14C-cytosine arabinoside (AraC) to rat brain by: 1) intraven

43 ibition of DNA synthesis with hydroxyurea or cytosine arabinoside (AraC) triggers a concerted repress

44 trikingly, when the DNA polymerase inhibitor cytosine arabinoside (araC) was added to wild-type infec

45 cephalic neurons, we compared the effects of cytosine arabinoside (AraC), a known neuronal apoptosis

46 sensitivity experiments with 5-fluorouracil, cytosine arabinoside (araC), and mercaptopurine (MP) dem

47 has been found by others that treatment with cytosine arabinoside (araC), but not aphidicolin, can al

48 1/S boundary were treated with pro-apoptotic cytosine arabinoside (araC), PP1alpha protein increased

49 We recently reported that cytosine arabinoside (AraC)-induced apoptosis of cerebel

50 utyl hydroperoxide or the anti-cancer agents cytosine arabinoside, bleomycin, melphalan, and cis-dich

51 chemotherapeutic agents [i.e. methotrexate, cytosine arabinoside (both free and liposomal) and thio-

52 mster cells to resistance against puromycin, cytosine arabinoside, colcemid, and methotrexate.

53 osphamide alone) or intensive (mitoxantrone, cytosine arabinoside, cyclophosphamide) priming on the c

54 ycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosp

55 bine (2',2'-difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a cla

56 (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE).

57 tected the BFU-e's from apoptosis induced by cytosine arabinoside, demonstrating that the SP600125 in

58 More importantly, cytosine arabinoside, ethidium bromide, 5-azacytidine an

59 in synthesis during a synchronous infection, cytosine arabinoside had no effect at concentrations suf

60 (ATRA) plus an anthracycline with or without cytosine-arabinoside has yielded complete response rates

61 derivatives of the nucleosides cytidine and cytosine arabinoside have been prepared from the corresp

62 O with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously administered, i

63 The addition of cytosine arabinoside improves outcome still further.

64 N-alpha, as well as that of HHT and low-dose cytosine arabinoside in patients failing IFN-alpha thera

65 ion of ARC promoted apoptosis and sensitized cytosine arabinoside-induced apoptosis in OCI-AML3 cells

66 nders human leukemic cells more resistant to cytosine arabinoside-induced apoptosis, whereas knockdow

67 lineage kinase inhibitor CEP-1347 prevented cytosine arabinoside-induced neuronal death, demonstrati

68 optosis of immature granule cells induced by cytosine arabinoside is not inhibited by the Egr inhibit

69 Cytarabine (cytosine arabinoside) is one of the most effective drugs

70 to genotoxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp874 by casp

71 mens and 10% with the BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) protocol.

72 tuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d

73 at treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial c

74 es and, when combined with either ABT-737 or cytosine arabinoside, provided substantial therapeutic b

75 n agreement with PI3K/AKT as an effector for cytosine arabinoside resistance in acute myeloid leukemi

76 ation with the chemotherapeutic agent Ara-C (cytosine arabinoside), restoration of miR-31-5p using G7

77 rther, a PI3-kinase inhibitor, LY294002, and cytosine arabinoside synergized in antileukemia effects

78 th induced by potassium deprivation, but not cytosine arabinoside, we asked whether the Egr inhibitor

79 Treatment of cells with cytosine arabinoside, which blocks the late buildup of d